Commonwealth Equity Services’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Commonwealth Equity Services’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,955	Closed	-$54K	–	3760
2021 Q3	$54K	Buy	12,955 +75	+0.6%	+$335	﹤0.01%	3494
2021 Q2	$68K	Buy	12,880 +95	+0.7%	+$457	﹤0.01%	3440
2021 Q1	$59K	Sell	12,785 -687	-5%	-$3.11K	﹤0.01%	3321
2020 Q4	$44K	Sell	13,472 -220	-2%	-$835	﹤0.01%	3138
2020 Q3	$45K	Sell	13,692 -1,500	-10%	-$5.51K	﹤0.01%	2953
2020 Q2	$51K	Sell	15,192 -400	-3%	-$1.89K	﹤0.01%	2848
2020 Q1	$59K	Sell	15,592 -3,200	-17%	-$14.9K	﹤0.01%	2661
2019 Q4	$113K	Buy	18,792 +700	+4%	+$4.79K	﹤0.01%	2727
2019 Q3	$136K	Buy	18,092 +4,600	+34%	+$51.8K	﹤0.01%	2632
2019 Q2	$182K	Buy	+13,492	New	+$156K	﹤0.01%	2528
2019 Q1	–	Sell	-14,420	Closed	-$42K	–	2794
2018 Q4	$42K	Buy	+14,420	New	+$79K	﹤0.01%	2577

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Commonwealth Equity Services's ZYNE Position: Q4 2021 in Review

Commonwealth Equity Services sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 12,955 shares — an estimated $54K sold.

Commonwealth Equity Services first reported a position in ZYNE in Q4 2018 and held it in 11 quarters. The position peaked at $182K in Q2 2019. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

Commonwealth Equity Services reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
Commonwealth Equity Services sold 12,955 Zynerba Pharmaceuticals, Inc shares in Q4 2021, an estimated $54K.
Commonwealth Equity Services first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and held it in 11 quarters.
Commonwealth Equity Services's Zynerba Pharmaceuticals, Inc position peaked at $182K in Q2 2019.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Commonwealth Equity Services's 13F filing for Q4 2021, filed 31 Jan 2022.